⌕
MoonLake Immunotherapeutics · MLTX · Nasdaq
Tenet 51 · Mixed
Compare
$11.73−6.16%At closeTenet 51 · Mixed
$11.73−0.77 (−6.16%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

MoonLake Immunotherapeutics (MLTX) Institutional Ownership

13F filers reported holding 88.4% of MoonLake Immunotherapeutics (MLTX) shares as of Jun 30, 2026, across 175 filers.

Sources Ownership filingsQuarter ended How we compute thisNot investment advice

4 figures withheld by our checks. Each blank figure names its reason.

Held by 13F filers
88.4%
Jun 30, 2026
13F filers
175
quarter ended Jun 30, 2026
13F value
$1.5B
75.2M shares

Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.

13F fund flowQuarter ended Jun 30, 2026. Withheld: many filers have already reported a later quarter, so their changes in this quarter are not on file and the counts of new, added, trimmed and closed positions are not shown. These positions are 140 days old; the 45-day figure often quoted is the SEC filing deadline after quarter-end, not the age of the data. The counts above compare each filer’s position with its own previous 13F. The change in the number of filers and in the ownership share is not shown: the filings we read hold only each filer’s latest 13F, so there is no earlier quarter of the same filers to compare against. That is a limit of the source, not a statement about this company.
Basis: shares reported by 175 13F filers for Jun 30, 2026, over shares outstanding implied from the current quote, measured 140 days apart. It measures the ownership we have filings for, not total institutional ownership, and it moves with the share count between filings.
routine sells are usually compensation mechanics; open-market buys are the rarer signal. Rows labelled with another security are the derivative leg of a vest or exercise, not share sales
DateNameRoleTypeSharesPriceSEC filing
Jul 27, 2026Reich KristianChief Scientific OfficerDisposed · Open-market sale1,100$20.00↗
Jul 22, 2026Reich KristianChief Scientific OfficerDisposed · Open-market sale2,448$20.00↗
Jul 21, 2026Reich KristianChief Scientific OfficerDisposed · Open-market sale50,000$20.02↗
Jul 20, 2026Reich KristianChief Scientific OfficerDisposed · Open-market sale43,700$20.09↗
Jul 15, 2026Reich KristianChief Scientific OfficerDisposed · Open-market sale16,105$20.01↗
Jul 10, 2026Santos da Silva JorgeChief Executive OfficerDisposed · Open-market sale68,289$20.02↗
Jul 9, 2026Santos da Silva JorgeChief Executive OfficerDisposed · Open-market sale33,936$20.01↗
Jul 1, 2026Santos da Silva JorgeChief Executive OfficerDisposed · Open-market sale47,775$20.03↗
Jun 22, 2026Bodenstedt MatthiasChief Financial OfficerDisposed · Open-market sale39,120$22.04↗
Jun 18, 2026Bodenstedt MatthiasChief Financial OfficerDisposed · Open-market sale2,794$19.60↗
Jun 17, 2026BVF PARTNERS L P/ILdirectorAcquired · Grant / award22,195Option to Buy—↗
Jun 17, 2026Bodenstedt MatthiasChief Financial OfficerDisposed · Open-market sale15,082$19.68↗
Jun 17, 2026Phillips Andrew JohndirectorAcquired · Grant / award22,195Option to Buy—↗
Jun 17, 2026Loy SpikedirectorAcquired · Grant / award22,195Option to Buy—↗
Jun 17, 2026Moukheibir CatherinedirectorAcquired · Grant / award22,195Option to Buy—↗
Jun 17, 2026Xavier RamnikdirectorAcquired · Grant / award22,195Option to Buy—↗
Jun 17, 2026Reich KristianChief Scientific OfficerDisposed · Open-market sale50,000$19.43↗
Jun 16, 2026Reich KristianChief Scientific OfficerDisposed · Open-market sale50,000$18.70↗
Jun 15, 2026Reich KristianChief Scientific OfficerDisposed · Open-market sale50,000$18.89↗
May 11, 2026Bodenstedt MatthiasChief Financial OfficerDisposed · Open-market sale13,653$20.02↗

* Holdings as reported for Jun 30, 2026, 140 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.

** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.

How much of MoonLake Immunotherapeutics do institutions hold?

13F filers reported holding 88.4% of MoonLake Immunotherapeutics' shares as of Jun 30, 2026, across 175 filers.

How many 13F filers hold MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics was held by 175 13F filers as of Jun 30, 2026.

Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.